Huan Xinkang, Zhan Jiuyu, Gao Hongwei
School of Life Science, Ludong University, Yantai, Shandong, China.
Front Immunol. 2024 Nov 18;15:1407149. doi: 10.3389/fimmu.2024.1407149. eCollection 2024.
The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity of the SARS-CoV-2 but also brings great obstacles to the treatment of COVID-19. Neutralizing antibodies have achieved good results in the clinical application of the novel coronavirus pneumonia, which can be used for pre-infection protection and treatment of novel coronavirus patients. This review makes a detailed introduction to the mutation characteristics of SARS-CoV-2, focusing on the molecular mechanism of mutation affecting the infectivity of SARS-CoV-2, and the impact of mutation on monoclonal antibody therapy, providing scientific reference for the prevention of SARS-CoV-2 variant strains and the research and development of antibody drugs.
2019冠状病毒病(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的一种具有很高感染率的呼吸道疾病。由于SARS-CoV-2易于变异,SARS-CoV-2变异株的不断出现不仅增强了SARS-CoV-2的传染性,也给COVID-19的治疗带来了巨大障碍。中和抗体在新型冠状病毒肺炎的临床应用中取得了良好效果,可用于新型冠状病毒感染前的预防及新型冠状病毒患者的治疗。本文详细介绍了SARS-CoV-2的突变特征,重点阐述了突变影响SARS-CoV-2传染性的分子机制以及突变对单克隆抗体治疗的影响,为预防SARS-CoV-2变异株及抗体药物研发提供科学参考。